--- title: Control the Cravings - The Official HCP Blog | CONTRAVE® (naltrexone HCI/bupropion HCI) description: Your online resource to help patients seeking to lose weight and control their cravings. Find out more about the obstacles your patients may face when trying to lose weight and identify which patients may be right for CONTRAVE. --- - [Prescribing Information](https://www.curraxpharma.com/PI/contrave-label-current.pdf) - [Medication Guide](https://www.curraxpharma.com/MG/contrave-label-current.pdf) - [For Patients](https://contrave.com/) [![Contrave logo](https://blog.contravehcp.com/hs-fs/hubfs/raw_assets/public/Contrave_HCP_ISI_DEPT_OG/images/LogoHCI.png?width=200&name=LogoHCI.png "Contrave logo")](https://contravehcp.com/) - [How CONTRAVE Works](https://contravehcp.com/how-contrave-works/) - Efficacy - [COR-BMOD study](https://contravehcp.com/efficacy/cor-bmod-study/) - [COR-I study](https://contravehcp.com/efficacy/cor-1-study/) - [COR-Diabetes study](https://contravehcp.com/efficacy/cor-diabetes-study/) - [Early responder efficacy](https://contravehcp.com/efficacy/early-responder-efficacy/) - [Safety](https://contravehcp.com/safety/) - [Real patient results](https://contravehcp.com/success-stories/) - [Dosing](https://contravehcp.com/dosing/) - Resources - [Prescribe authentic CONTRAVE](https://contravehcp.com/prescribeauthenticcontrave/) - [Obesity Discussion Guide](https://contravehcp.com/obesity-discussion-guide/) - [Downloadable resources](https://contravehcp.com/resources/) - [Blog](https://blog.contravehcp.com/) - [FAQs](https://contravehcp.com/faqs/) - [SAVINGS & SUPPORT](https://contravehcp.com/savings-and-support/) - [2 WAYS TO SAVE](https://contravehcp.com/savings-and-support/) [![Contrave logo](https://blog.contravehcp.com/hs-fs/hubfs/raw_assets/public/Contrave_HCP_ISI_DEPT_OG/images/LogoHCI.png?width=200&name=LogoHCI.png "Contrave logo")](https://contravehcp.com/) [2 WAYS TO SAVE](https://contravehcp.com/savings-and-support/) - [How CONTRAVE Works](https://contravehcp.com/how-contrave-works/) - Efficacy - [COR-BMOD study](https://contravehcp.com/efficacy/cor-bmod-study/) - [COR-I study](https://contravehcp.com/efficacy/cor-1-study/) - [COR-Diabetes study](https://contravehcp.com/efficacy/cor-diabetes-study/) - [Early responder efficacy](https://contravehcp.com/efficacy/early-responder-efficacy/) - [Safety](https://contravehcp.com/safety/) - [Real patient results](https://contravehcp.com/success-stories/) - [Dosing](https://contravehcp.com/dosing/) - Resources - [Prescribe authentic CONTRAVE](https://contravehcp.com/prescribeauthenticcontrave/) - [Obesity Discussion Guide](https://contravehcp.com/obesity-discussion-guide/) - [Downloadable resources](https://contravehcp.com/resources/) - [Blog](https://blog.contravehcp.com/) - [FAQs](https://contravehcp.com/faqs/) - [SAVINGS & SUPPORT](https://contravehcp.com/savings-and-support/) - [2 WAYS TO SAVE](https://contravehcp.com/savings-and-support/) --- - [Prescribing Information](https://www.curraxpharma.com/PI/contrave-label-current.pdf) - [Medication Guide](https://www.curraxpharma.com/MG/contrave-label-current.pdf) - [For Patients](https://contrave.com/) - [How CONTRAVE Works](https://contravehcp.com/how-contrave-works/) - Efficacy - [COR-BMOD study](https://contravehcp.com/efficacy/cor-bmod-study/) - [COR-I study](https://contravehcp.com/efficacy/cor-1-study/) - [COR-Diabetes study](https://contravehcp.com/efficacy/cor-diabetes-study/) - [Early responder efficacy](https://contravehcp.com/efficacy/early-responder-efficacy/) - [Safety](https://contravehcp.com/safety/) - [Real patient results](https://contravehcp.com/success-stories/) - [Dosing](https://contravehcp.com/dosing/) - Resources - [Prescribe authentic CONTRAVE](https://contravehcp.com/prescribeauthenticcontrave/) - [Obesity Discussion Guide](https://contravehcp.com/obesity-discussion-guide/) - [Downloadable resources](https://contravehcp.com/resources/) - [Blog](https://blog.contravehcp.com/) - [FAQs](https://contravehcp.com/faqs/) - [SAVINGS & SUPPORT](https://contravehcp.com/savings-and-support/) - [2 WAYS TO SAVE](https://contravehcp.com/savings-and-support/) # Control the cravings Here are some online resource to help patients seeking to lose weight and control their cravings. Find out more about the obstacles your patients may face when trying to lose weight and identify which patients may be right for CONTRAVE. Filter by topic: - [All](https://blog.contravehcp.com/) - [Advocacy](https://blog.contravehcp.com/tag/advocacy) - [Education](https://blog.contravehcp.com/tag/education) - [Healthcare](https://blog.contravehcp.com/tag/healthcare) - [Individualized care](https://blog.contravehcp.com/tag/individualized-care) - [Lifestyle](https://blog.contravehcp.com/tag/lifestyle) - [Support](https://blog.contravehcp.com/tag/support) [Healthcare](https://blog.contravehcp.com/tag/healthcare), [Education](https://blog.contravehcp.com/tag/education), [Individualized Care](https://blog.contravehcp.com/tag/individualized-care) ## [The Relationship Between Sleep & Weight](https://blog.contravehcp.com/the-relationship-between-sleep-and-weight) Nutrition and physical activity are the two health behaviors that garner the most attention... 2 minute read [Read More](https://blog.contravehcp.com/the-relationship-between-sleep-and-weight) [Lifestyle](https://blog.contravehcp.com/tag/lifestyle), [Healthcare](https://blog.contravehcp.com/tag/healthcare), [Individualized Care](https://blog.contravehcp.com/tag/individualized-care) ## [Ask the Right Questions to Uncover Emotional Eating](https://blog.contravehcp.com/ask-the-right-questions-to-uncover-emotional-eating) Do you struggle with starting the weight loss conversation with your patients? Are you able to... 2 minute read [Read More](https://blog.contravehcp.com/ask-the-right-questions-to-uncover-emotional-eating) [Healthcare](https://blog.contravehcp.com/tag/healthcare), [Individualized Care](https://blog.contravehcp.com/tag/individualized-care) ## [Tips for Starting the Conversation Around Weight Loss](https://blog.contravehcp.com/tips-for-starting-the-conversation-around-weight-loss) For many patients, talking about weight loss with a healthcare provider's office is something to... 1 minute read [Read More](https://blog.contravehcp.com/tips-for-starting-the-conversation-around-weight-loss) [Healthcare](https://blog.contravehcp.com/tag/healthcare), [Support](https://blog.contravehcp.com/tag/support) ## [How To Help Your Patients Save](https://blog.contravehcp.com/how-to-help-your-patients-save) Everyone has been feeling the effects of prices skyrocketing. From groceries to gas, and even... 2 minute read [Read More](https://blog.contravehcp.com/how-to-help-your-patients-save) [Healthcare](https://blog.contravehcp.com/tag/healthcare), [Advocacy](https://blog.contravehcp.com/tag/advocacy), [Individualized Care](https://blog.contravehcp.com/tag/individualized-care) ## [Creating a Size-Inclusive Environment In Your Practice](https://blog.contravehcp.com/creating-a-size-inclusive-environment-in-your-practice) A challenge for healthcare professionals today is ensuring that the language used when talking to... 1 minute read [Read More](https://blog.contravehcp.com/creating-a-size-inclusive-environment-in-your-practice) [Support](https://blog.contravehcp.com/tag/support), [Education](https://blog.contravehcp.com/tag/education), [Individualized Care](https://blog.contravehcp.com/tag/individualized-care) ## [How To Work As Part Of A Weight Loss Care Team](https://blog.contravehcp.com/how-to-work-with-weight-loss-care-team) Losing weight is no longer something people need to power through alone. Medically supported weight... 1 minute read [Read More](https://blog.contravehcp.com/how-to-work-with-weight-loss-care-team) [Lifestyle](https://blog.contravehcp.com/tag/lifestyle), [Healthcare](https://blog.contravehcp.com/tag/healthcare), [Support](https://blog.contravehcp.com/tag/support), [Advocacy](https://blog.contravehcp.com/tag/advocacy), [Individualized Care](https://blog.contravehcp.com/tag/individualized-care) ## [A Guide to Supporting Patients Starting Weight Loss Therapy](https://blog.contravehcp.com/a-guide-to-supporting-patients-starting-weight-loss-therapy) For your patients who are starting on a new prescription weight loss medication, getting started... 2 minute read [Read More](https://blog.contravehcp.com/a-guide-to-supporting-patients-starting-weight-loss-therapy) Important Safety Information Indication See More  ### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS ### Suicidality and Antidepressant Drugs **CONTRAVE® is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on CONTRAVE, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. CONTRAVE is not approved for use in pediatric patients.** CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. Important Safety Information and Indication See More ### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS ### Suicidality and Antidepressant Drugs **CONTRAVE® is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on CONTRAVE, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. CONTRAVE is not approved for use in pediatric patients.** Indication See More CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or who are overweight in the presence of at least one weight-related comorbid condition. Important Safety Information AND INDICATION Indication See Less  ### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS ### Suicidality and Antidepressant Drugs **CONTRAVE® is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on CONTRAVE, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. CONTRAVE is not approved for use in pediatric patients.** ### Contraindications CONTRAVE is contraindicated in: uncontrolled hypertension; seizure disorder or a history of seizures; use of other bupropion-containing products; bulimia or anorexia nervosa, which increase the risk for seizure; chronic opioid or opiate agonist (eg, methadone) or partial agonist (eg, buprenorphine) use, or acute opiate withdrawal; patients undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs; use during/within 14 days following treatment with monoamine oxidase inhibitors (MAOIs), as there is an increased risk of hypertensive reactions when CONTRAVE is used concomitantly with MAOIs, including reversible MAOIs such as linezolid or intravenous methylene blue; known allergy to any component of CONTRAVE, as anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported. ### WARNINGS AND PRECAUTIONS ### Suicidal Behavior and Ideation **All patients being treated with antidepressants for any indication should be monitored and observed for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes.** **Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of suicidality, anxiety, agitation, irritability, unusual changes in behavior, and other symptoms, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for CONTRAVE should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.** ### Neuropsychiatric Adverse Events and Suicide Risk in Smoking Cessation Treatment CONTRAVE is not approved for smoking cessation. Serious neuropsychiatric adverse events have been reported in patients taking bupropion for smoking cessation. These postmarketing reports have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Some patients who stopped smoking may have been experiencing symptoms of nicotine withdrawal, including depressed mood. Depression, rarely including suicidal ideation, has been reported in smokers undergoing a smoking cessation attempt without medication. However, some of these adverse events occurred in patients taking bupropion who continued to smoke. Neuropsychiatric adverse events occurred in patients without and with pre-existing psychiatric disease; some patients experienced worsening of their psychiatric illnesses. Observe patients for the occurrence of neuropsychiatric adverse events. Advise patients and caregivers that the patient should stop taking CONTRAVE and contact a healthcare provider immediately if agitation, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior. ### Seizures Bupropion, a component of CONTRAVE, can cause seizures. The risk of seizure is dose-related. Discontinue treatment and do not restart CONTRAVE in patients who experience a seizure. Use caution when prescribing CONTRAVE to patients with an elevated risk of seizure, including: history of head trauma or prior seizure, severe stroke, arteriovenous malformation, central nervous system tumor or infection, or metabolic disorders (eg, hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia); excessive use of alcohol or sedatives, addiction to cocaine or stimulants, or withdrawal from sedatives; patients with diabetes treated with insulin and/or oral diabetic medications (sulfonylureas and meglitinides) that may cause hypoglycemia; concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic steroids. Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended dosing recommendations, in particular: the total daily dose of CONTRAVE does not exceed 360 mg of the bupropion component (ie, four tablets per day); the daily dose is administered in divided doses (twice daily); the dose is escalated gradually; no more than two tablets are taken at one time; coadministration of CONTRAVE with high-fat meals is avoided; if a dose is missed, a patient should wait until the next scheduled dose to resume the regular dosing schedule. ### Patients Receiving Opioid Analgesics **Vulnerability to Opioid Overdose:** CONTRAVE should not be administered to patients receiving chronic opioids, due to the naltrexone component, which is an opioid receptor antagonist. If chronic opiate therapy is required, CONTRAVE treatment should be stopped. In patients requiring intermittent opiate treatment, CONTRAVE therapy should be temporarily discontinued and lower doses of opioids may be needed. Patients should be alerted that they may be more sensitive to opioids, even at lower doses, after CONTRAVE treatment is discontinued. An attempt by a patient to overcome any naltrexone opioid blockade by administering large amounts of exogenous opioids is especially dangerous and may lead to a fatal overdose or life-threatening opioid intoxication (e.g., respiratory arrest, circulatory collapse). Patients should be told of the serious consequences of trying to overcome the opioid blockade. **Precipitated Opioid Withdrawal:** An opioid-free interval of a minimum of 7 to 10 days is recommended for patients previously dependent on short-acting opioids, and those patients transitioning from buprenorphine or methadone may need as long as two weeks. Patients should be made aware of the risks associated with precipitated withdrawal and encouraged to give an accurate account of last opioid use. ### Increase in Blood Pressure (BP) and Heart Rate (HR) CONTRAVE can cause an increase in systolic BP, diastolic BP, and/or resting HR. These events were observed in both patients with and without evidence of preexisting hypertension. In clinical practice with other bupropion-containing products, hypertension, in some cases severe and requiring acute treatment, has been reported. Blood pressure and pulse should be measured prior to starting therapy with CONTRAVE and should be monitored at regular intervals consistent with usual clinical practice, particularly among patients with controlled hypertension prior to treatment. ### Allergic Reactions Anaphylactoid/anaphylactic reactions and symptoms suggestive of delayed hypersensitivity have been reported with bupropion, as well as rare spontaneous reports of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock. Instruct patients to discontinue CONTRAVE and consult a healthcare provider if they develop an allergic or anaphylactoid/anaphylactic reaction (eg, skin rash, pruritus, hives, chest pain, edema, or shortness of breath) during treatment. ### Hepatotoxicity Cases of hepatitis, clinically significant liver dysfunction, and transient asymptomatic hepatic transaminase elevations have been observed with naltrexone exposure. Warn patients of the risk of hepatic injury and advise them to seek medical attention if they experience symptoms of acute hepatitis. Use of CONTRAVE should be discontinued in the event of symptoms and/or signs of acute hepatitis. ### Activation of Mania Bupropion, a component of CONTRAVE, is a drug used for the treatment of depression. Antidepressant treatment can precipitate a manic, mixed, or hypomanic episode. The risk appears to be increased in patients with bipolar disorder or who have risk factors for bipolar disorder. Prior to initiating CONTRAVE, screen patients for history of bipolar disorder and the presence of risk factors for bipolar disorder (eg, family history of bipolar disorder, suicide, or depression). CONTRAVE is not approved for use in treating bipolar depression. ### Angle-Closure Glaucoma The pupillary dilation that occurs following use of many antidepressant drugs, including bupropion, may trigger an angle-closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. ### Hypoglycemia With Use of Antidiabetic Medications Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes mellitus treated with insulin and/or insulin secretagogues (eg, sulfonylureas). Measurement of blood glucose levels prior to starting CONTRAVE and during CONTRAVE treatment is recommended in patients with type 2 diabetes. Decreases in medication doses for antidiabetic medications that are non-glucose-dependent should be considered to mitigate the risk of hypoglycemia. ### Adverse Reactions Most common adverse reactions (≥5%) include: nausea (32.5%), constipation (19.2%), headache (17.6%), vomiting (10.7%), dizziness (9.9%), insomnia (9.2%), dry mouth (8.1%), and diarrhea (7.1%). ### Drug Interactions Use caution and consider dose reduction of drugs metabolized by CYP2D6 when using with CONTRAVE. Avoid concomitant use with MAOIs and CYP2B6 inducers. Reduce CONTRAVE dose when taken with CYP2B6 inhibitors. Dose CONTRAVE with caution when used with drugs that lower seizure threshold. Use caution and monitor for CNS toxicity when using CONTRAVE concomitantly with dopaminergic drugs (levodopa and amantadine). CONTRAVE can cause false positive urine test results for amphetamines. ### Indication CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or who are overweight in the presence of at least one weight-related comorbid condition. ### Limitations of Use The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. CONTRAVE contains naltrexone and bupropion. Coadministration with other naltrexone-containing products is not recommended. Coadministration with other bupropion-containing products is contraindicated. **Please see [Full Prescribing Information](https://www.curraxpharma.com/PI/contrave-label-current.pdf) for complete Boxed Warning and [Medication Guide](https://www.curraxpharma.com/MG/contrave-label-current.pdf/) for CONTRAVE.** [![Currax Pharmaceuticals LLC Logo](https://blog.contravehcp.com/hubfs/raw_assets/public/Contrave_HCP_ISI_DEPT_OG/images/Currax-logo.svg "Currax Pharmaceuticals LLC Logo")](http://www.curraxpharma.com/) CONTRAVE® is a registered trademark of Currax Pharmaceuticals LLC. All other trademarks are the property of their respective owners. © 2025 Currax Pharmaceuticals LLC.   CON-2071-001  04/2024 - [Site Map](https://contravehcp.com/site-map/) - [About Currax Pharmaceuticals LLC](https://www.curraxpharma.com/meet-us/) - [Contact Us](http://www.curraxpharma.com/contact-us/?__hstc=162194915.63e604c120b04d1f0893160a2dd72734.1662788715026.1662790777182.1662793838477.3&__hssc=162194915.5.1662793838477&__hsfp=69242381) - [Terms of Use](http://www.curraxpharma.com/policies/terms-of-use/?__hstc=162194915.63e604c120b04d1f0893160a2dd72734.1662788715026.1662790777182.1662793838477.3&__hssc=162194915.5.1662793838477&__hsfp=69242381) - [Privacy Policy](http://www.curraxpharma.com/policies/privacy-policy/?__hstc=162194915.63e604c120b04d1f0893160a2dd72734.1662788715026.1662790777182.1662793838477.3&__hssc=162194915.5.1662793838477&__hsfp=69242381) Follow Us: - [![](https://blog.contravehcp.com/hubfs/raw_assets/public/Contrave_HCP_ISI_DEPT_OG/images/facebook.png)](https://www.facebook.com/ContraveOfficialPage/) - [![](https://blog.contravehcp.com/hubfs/raw_assets/public/Contrave_HCP_ISI_DEPT_OG/images/instagram.png)](https://www.instagram.com/CONTRAVE_rx/) - [![](https://blog.contravehcp.com/hubfs/raw_assets/public/Contrave_HCP_ISI_DEPT_OG/images/youtube.png)](https://www.youtube.com/@CONTRAVEOfficial)